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Abstract
BACKGROUND: When planning radioactive iodine therapy, it 
frequently happens, both in Poland and world-wide, that inad-
equate attention is paid to such easily measurable parameters 
as: 1) the serum concentration of thyrotropin (TSH) before 
administering radioiodine, which is a key factor for extranodular 
(non-autonomous) iodine uptake of the thyroid gland, 2) thyroid 
gland iodine uptake, and 3) the effective half-life of 131I (Teff.). The 
aim of the study is to evaluate the impact of the above factors 
on the efficacy of 131I treatment in hyperthyroid patients.
METHODS: The material consisted of 4140 patients: 2190 with 
autonomous toxic nodules (ATN) and 1950 with toxic multinodu-
lar goitres (TMG). The patients were prepared for treatment in 
such a way that the concentration of TSH did not exceed 0.1 mU/l 
and Teff.< 5 days. The therapeutic activity of 
131I was calculated 
using Marinelli’s formula. The selection of absorbed dose value 
was determined by the degree of suppression of extranodular 
tissue. Monitoring was performed every eight weeks. 
RESULTS: At one year after 131I administration showed that 
a euthyroid status was achieved in 94%, hypothyroidism was 
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seen observed in 3%, while persistence or recurrence of hyper-
thyroidism in 3% of ATN patients and, respectively, 89%, 4% and 
7% of TMG patients.
CONCLUSIONS: Patients with toxic nodular goitre who are to be 
treated with radioiodine should have the lowest possible serum 
concentration of TSH. The suppression of extranodular deter-
mines the optimal value of absorbed dose for Marinelli’s formula. 
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Introduction
In spite of the fact that radioiodine has been employed for the 
treatment of hyperthyroidism for over sixty years, and although 
numerous studies all over the world seem to have provided 
a comprehensive view of various aspects of this therapy, a uniform 
standard of procedures has not been developed as yet. The lack 
of agreement as to radioiodine treatment of hyperthyroidism fre-
quently results from the fact that specialists do not make adequate 
use of knowledge concerning the pathophysiology of the thyroid 
gland or data on the interaction of ionising radiation with organic 
matter. Admittedly, we still do not have a method to assess the 
radiosensitivity of the treated gland, but many hospitals — both in 
Poland and abroad — neglect other, equally important and easily 
measurable, parameters such as: 
 — concentration of thyrotropin (TSH) in the blood serum of pa-
tients with toxic nodular goitre before radioiodine administra-
tion, crucial for stimulation of extranodular (non-autonomous) 
iodine uptake by thyroid gland tissue [1–2];
 — thyroidal iodine uptake, with particular attention to the dyna-
mics of its change, whose indicator is the effective half-life of 
131I (Teff.)[3–4]. 
The above parameters determine the optimal dose of 131I ab-
sorbed by the thyroid gland. And it is indisputable that the effect 
of ionising radiation on thyroid tissue depends on the absorbed 
dose. Its increase results, among other things, in a reduction of 
both the hormonal function of the thyroid gland and its size. 
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The purpose of this study is to evaluate the impact of the above 
mentioned factors on the efficacy of (131I) treatment in hyperthyroid 
patients. This evaluation was based on a retrospective analysis of 
the outcome of over 4,000 radioiodine therapy patients. 
Methods 
The material consisted of 4140 patients who, between the 
years 1998 and 2010, underwent radioactive iodine 131I therapy 
for hyperthyroidism in the Nuclear Medicine Clinic of the Medical 
University of Bialystok.
Based on scintigraphy and ultrasonography results, the ana-
lysed cases were divided into two subgroups. Group I was com-
prised of 2190 persons with autonomous toxic nodule (ATN), while 
in group II there were 1950 patients with toxic multinodular goitre 
(TMG) Eligibility for radioiodine therapy was determined on the 
basis of typical hyperthyroidism symptoms — both clinical and 
biochemical, i.e. elevated levels of free triiodothyronine (fT3) and 
free thyroxine (fT4), as well as reduced serum levels of TSH. All 
nodules detected by USG were diagnosed through fine needle 
aspiration biopsy in order to exclude malignancy. It was assumed 
that treatment could be commenced if a patient’s TSH level 
was below 0.1 mIU/L, 24h iodine uptake was higher than 20% 
(T24 > 20%), and the effective half-life of 
131I (Teff.), calculated from 
iodine uptake measurements 24 and 48 hours (T24 and T48) after 
the administration of the diagnostic dose, exceeded 5 days. Those 
patients whose fT4 had been markedly elevated were pretreated 
with antithyroid drugs for 2–3 weeks, the pretreatment being dis-
continued 2–3 days before radioiodine administration [5–6]. The 
therapeutic activity of 131I was calculated using Marinelli’s formula 
(D) [7]:
A = 
25 × m × D
T24 × Teff
where:
A — 131I therapeutic activity (MBq)
25 — unit conversion coefficient  
m — volume of thyroid gland calculated from USG (g) 
D – absorbed dose (Gy)
T24 — 24-h
 131I uptake (%)
Teff — effective 
131I half-life in thyroid gland (days) = Tbiolog x Tphys/ 
/Tbiolog+ Tphys, where Tbiolog
 (rate of iodine excretion from the thyroid), 
Tphys (physical half-life of radioactive iodine) 
It was assumed that the absorbed dose from Marinelli’s for-
mula is closely correlated with the ratio of radioiodine uptake in 
nodules to radioiodine uptake in the entire gland. This ratio is fur-
ther referred to as a percentage of radioiodine uptake in nodule 
(Figures 1–3). The formula for this relation is: 
 D = P × 400 Gy,
where:
D — absorbed dose  
P — percentage of radioiodine uptake in nodules, expressed 
as a common fraction  
400 Gy — maximum absorbed dose for autonomous toxic 
nodule(s), as agreed in the literature [8] 
The volume of the gland assessed by USG was calculated 
using the usual formula for the volume of a spheroid [9]:  
Figure 1. ATN scintigram with 100% radioiodine uptake in nodule 
(I degree of suppression of extranodular tissue). Calculated absorbed 
dose used in Marinelli’s formula is: D = 400 Gy x 100% Æ 400 Gy 
Figure 2. ATN scintigram with 75% radioiodine uptake in nodule (II de-
gree of suppression of extranodular tissue. Calculated absorbed dose 
used in Marinelli’s formula is: D = 400 Gy x 75% Æ 280 Gy 
Figure 3. ATN scintigram with 50% radioiodine uptake in nodule (III 
degree of suppression of extranodular tissue). Calculated absorbed 
dose used in Marinelli’s formula is: D = 400 Gy x 50% Æ 200 Gy  
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V =
4p × a × b × c
3
where:
a, b, c — size of thyroid lobes (length, width, thickness) 
The calculated 131I therapeutic activities were administered 
orally in the form of capsules. In Poland, the only available 
capsules are (MBq): 200, 280, 400, 600 and 800. If the activity 
calculated from the formula proved to be much higher than that 
available, and amounted to the maximum ambulatory dose, 
additional 131I doses were not administered until after 6 months.  
The patients underwent medical check-ups every 8 weeks with-
in a year after 131I administration. Additionally, 400 persons were 
randomly selected from the analysed group and, after 3 and 
5 years following radioactive iodine administration, tested for fT4, 
fT3 and TSH blood levels in order to evaluate possible changes in 
the percentage of euthyroid, hypothyroid and hyperthyroid pa-
tients which may have occurred in the time interval. 
Statistical analysis 
All statistic analyses were performed using the software pack-
age Statistica 9 (Stat Soft, Kraków, Poland). 
 General comparison of the two (ATN, TMG) groups in terms of 
gender, euthyroidism, hypothyroidism and hyperthyroidism after 1, 
3 and 5 years from the commencement of therapy was performed 
using the c2 test, whereas the Mann-Whitney test was used for 
comparison in terms of age. 
In order to assess the proportion of euthyroid, hypothyroid 
and hyperthyroid patients depending on sex, age, thyroid gland 
volume, radioiodine effective half-life and uptake in nodule, the c2 
test was employed separately for both groups. 
Friedman’s test was used to estimate the difference between 
fT4, fT3, TSH levels at 2 weeks before treatment and those observed 
in the subsequent months after 131I administration. 
Moreover, the logistic regression model was used to evaluate 
the degree to which independent variables (gland volume, T24, Teff., 
radioiodine uptake in nodule) affected the likelihood of recovery 
(i.e. restoring euthyroidism). The influence of the same variables on 
the probability of hypothyroidism was assessed analogically. 
Results 
Table 1 presents a summary of the characteristics of the 
patients who were included in the sample, divided into sub-
groups based on type of hyperthyroidism, gender and age.  
The table shows that the proportions of men and women 
were similar for both groups, but that the TMG patients were 
older (p < 0.05).  
The assessment of the overall efficacy of treatment at 
one year after 131I administration showed that a euthyroid sta-
tus was achieved in 94%, hypothyroidism was observed in 3%, 
while persistence or recurrence of hyperthyroidism in 3% of pa-
tients with autonomous toxic nodules. In toxic multinodular goitre 
patients however the efficacy was slightly lower (p < 0.05) and 
amounted to 89%, 4%, 7% respectively. This outcome meant that 
further treatment was necessary only in 7% of TMG patients and 
in 3% of ATN cases (Figure 4). 
As the time after radioiodine administration elapses, the 
percentage of hypothyroid patients increases. And thus, 
3 years after 131I administration the proportion of such patients in 
the ATN subgroup was 9%, while 5 years after the treatment it 
rose to 11%. In the TMG subgroup, the percentage was 11% and 
16% respectively. This amounts to an average annual increase 
of 1.6% (ATN) and 2.4% (TMG) in hypothyroidism among the 
study sample (Figure 5). 
Tables 2 and 3 show that neither gender nor age had a signifi-
cant influence on the final outcome of hyperthyroidism treatment. 
The best therapeutic results, i.e. the highest euthyroidism rate 
and the lowest persistent hyperthyroidism rate, were obtained in 
patients with autonomous adenoma and with considerable sup-
pression of healthy tissue surrounding the nodule. 
It was also established that a correlation exists between 
therapeutic outcome and the effective half-life of 131I. The highest 
efficacy was obtained in patients treated with radioiodine which 
had at least a 7-day effective half-life. 
The lowest proportion of hypothyroidism and, at the same 
time, the lowest efficacy was observed in patients with large and 
very large glands (above 60 ml). 
Table 1. General profile of 4140 patients with toxic nodular goitre treated with 131I
Diagnosis Female Male Value p Age (year) 
min–max
X
–
Value p
n % N %
ATN 1883 86 307 14
SI
20–80 59
< 0.05
TMG 1626 83 324 17 34–88 67
ATN — autonomus toxic nodule; TMG — toxic multinodular goitre; SI — statistically insignificant
Figure 4. Comprehensive presentation of efficacy of 131I therapy in 
TNG patients at 1 year after radioiodine administration
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The least beneficial effects were seen in multinodular goi-
tres with a low rate of radioiodine uptake in nodules, relative to 
the uptake in the entire thyroid gland. 
The logistic regression model was used to demonstrate that 
three factors have a significant impact on restoration of euthy-
roidism: percentage of radioiodine uptake in nodule, T24 and Teff. 
levels and the volume of the thyroid gland. To be more precise, the 
chances of achieving euthyroidism grow 3.6 times when radioiodine 
uptake in nodule is moved up one level, 2-fold when T24 and Teff. 
concentrations rise, and 1.5 times when the volume of the thyroid 
increases (Table 4). Whereas, hypothyroidism is most likely to de-
velop when the rate of radioiodine uptake in nodules is low. With 
a 1% rise in the rate of radioiodine uptake in nodule, the probability of 
hypothyroidism occurring after treatment drops 0.31 times (Table 5). 
The primary objective of radioiodine therapy is to eliminate 
hyperthyroidism, but what is significant for patients is the quick-
ness of therapeutic effect. Figures 6, 7 and 8 illustrate the dyna-
mics of change in mean concentrations of TSH, fT3 and fT4 after 
treatment with 131I.
Both groups revealed a statistically significant decrease 
(p < 0.001) in fT3 and fT4 blood levels as early as approxi-
mately two months after radioiodine administration. Moreover, 
the concentration of these hormones continued to remain 
within normal range throughout the studied period. It should 
be emphasised that TSH serum values reached normal lev-
els much later than those of fT3 and fT4, i.e. after 4 months in 
the case of solitary nodules and after 7 months in the case 
of multinodular goitres. 
Figure 5. Efficacy dynamics of 131I therapy in ATN(a) and TMG(b) over time
Table 2. Results of treatment of 2190 patients with ATN according to gender, age, volume of thyroid, effective 131I half-life and radioiodine 
uptake in nodule
Outcome
Euthyreoidism Hypothyreoidism Hyperthyreoidism Value p
Gender
Female
Male
1802 (94%)
251 (92%)
57 (3%)
11 (4%)
58 (3%)
11 (4%)
SI
Age (year)
< 40 
40–60
> 60
285 (93%)
403 (92%)
1358 (94%)
9 (3%)
13 (3%)
43 (3%)
13 (4%)
22 (5%)
44 (3%)
SI
Thyroid volume [cm3]
20–30
30–60
60–90
780 (89%)
1040 (95%)
195 (89%)
87 (10%)
22 (2%)
1 (0.5%)
9 (1%)
33 (3%)
23 (10.5%)
< 0.005
Effective half-life 131I -Teff. (day)
5–7
> 7
197 (90%)
1833 (94%)
11 (5%)
118 (5.5%)
11 (5%)
20 (0.5%)
< 0.005
Percentage of radioiodine uptake
I° [80–100%]
II° [60–80%]
III° [40–60%]
532 (99%)
811 (92%)
647 (84%)
3 (0.5%)
40 (4.5%)
77 (10%)
3 (0.5%)
31 (3.5%)
46 (6%)
< 0.005
SI — statistically insignificant
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Discussion 
The obtained results indicate that the efficacy of 131I treatment 
for hyperthyroidism in both solitary nodules and multinodular goi-
tres is slightly higher in our Department than in other European in-
stitutions of the same type [10–13]. The proportion of patients with 
autonomous solitary nodules and multinodular goitres who were 
cured of hyperthyroidism within a year of starting therapy amounted 
to 94% and 89%, respectively, and remained as high as 80–90% 
throughout the five-year period following therapy. It seems that the 
Table 3. Results of treatment of 2190 patients with TMG according to gender, age volume of thyroid, effective 131I half-life and radioiodine 
uptake in nodule
Outcome
Euthyreoidism Hypothyreoidism Hiperthyreoidism Value p
Gender
Female
Male
3297 (91%)
465 (90%)
108 (3%)
21 (4%)
218 (6%)
31 (6%)
SI
Age (year)
< 40 
40–60
> 60
175 (90%)
210 (90%)
1424 (91%)
8 (4%)
10 (4%)
47 (3%)
12 (6%)
14 (6%)
94 (5%)
SI
Thyroid volume [cm3]
20–30
30–60
60–90
201 (86%)
1100 (94%)
486 (89%)
28 (12%)
35 (3%)
3 (0.5%)
5 (2%)
35 (3%)
57 (10.5%)
< 0.005
Effective half-life I-131-Teff. (day)
5–7
> 7
210 (90%)
1596 (93%)
12 (5%)
103 (6%)
12 (5%)
17 (1%)
< 0.005
Percentage of radioiodine uptake
I° [80–100%]
II° [60–80%]
III° [40–60%]
213 (98%)
562 (91%)
892 (80%)
2 (1%)
31 (5%)
134 (12%)
2(1%)
25(4%)
89 (8%)
< 0.005
SI — statistically insignificant
Table 4. Evaluation of the influence of particular factors (through 
calculation of adjusted odds ratio) on achieving euthyroidism in 
patients with TMG and ATN after one-year treatment
AOR 95% CI Value p
Thyroid volume 1.5 1.19–2.2 0.005
T24 1.03 1.23–2.47 0.002
Teff. 1.8 1.71–2.56 < 0.001
Percentage of  
radioiodine uptake
3.6 2.88–4.02 < 0.001
AOR — adjusted odds ratio
Table 5. Evaluation of the influence of particular factors (through 
calculation of adjusted odds ratio) on achieving hypothyroidism in 
patients with TMG and ATN after one-year treatment
AOR 95% CI Value p
Thyroid volume 0.4 0.25–0.5 0.005
T24 0.98 0.76–0.99 0.002
Teff. 0.87 0.74–0.94 < 0.001
Percentage of  
radioiodine uptake
0.31 0.2–0.39 < 0.001
Figure 6. Changes in mean concentrations of TSH in studied patients 
within 12 months after 131I administration
Figure 7. Changes in mean concentrations of fT3 in studied patients 
within12 months after 131I administration
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high rate of successful treatment of hyperthyroidism is a result of 
the clinical protocol designed in our Department.
The overriding objective of our standards of treatment for hyper-
thyroidism is to obtain the highest possible proportion of euthyroid 
patients with the fewest possible cases of hypo- or hyperthyroidism. 
This approach is somewhat different from that employed by other 
European authors, particularly British ones, for whom the primary 
goal of treatment is the elimination of hyperthyroidism (achieving 
either euthyroidism or hypothyroidism), the ratio of euthyroid to hy-
pothyroid glands notwithstanding. For this reason, many studies re-
veal a fairly high percentage of hypothyroid patients — 15–25% after 
radioiodine therapy [14–16]. Our results show that the proportion of 
hypothyroidism in both types of goitre does not exceed 5% a year 
after therapy and 16% five years after therapy. The reason for the 
low percentage of post-therapy hypothyroidism in our Department 
is that we follow certain basic principles. 
First and foremost, we take steps to prepare patients for the 
131I treatment in such a way that after the radioiodine capsule 
is ingested, the radiation energy is absorbed entirely, or primarily, 
by autonomous nodules.  
We regard achieving the lowest possible TSH serum value 
as an essential part of patient preparation. Our Department 
treats only patients with TSH < 0.1 IU/ml, which minimises iodine 
uptake and potential radiation-induced damage of the tissue sur-
rounding the nodules [2]. The prerequisite of low TSH is frequently 
overlooked in other studies. What seems to further confirm this ob-
servation is the fact that those studies recommend discontinuation 
of antithyroid drugs merely days before the planned administration 
of radioiodine. As is well known, antithyroid drugs medications first 
of all inhibit the function of autonomous thyroid nodules and, 
as a consequence, enhance the action of the pituitary gland, which 
results in elevated TSH secretion thereby stimulating radioiodine 
uptake in normal tissue and leads to needless damage or de-
struction. That is why the outcomes presented in the mentioned 
studies are relatively worse than ours. Namely, they report a higher 
percentage of hypothyroid patients, amounting even to 45% at one 
year after radioiodine therapy in our Department, hypothyroidism 
was observed in 3% of ATN patients and 4% of TMG patients.
Proper qualification of patients with severe hyperthyroid symp-
toms should involve bringing the levels of the thyroid hormones (thy-
roxine and triiodothyronine) within the normal range. For this reason, 
some cases require preliminary but short-term (2–3 days) treatment 
with antithyroid drugs in order to lower the concentrations of fT4 and 
fT3 in serum and in the thyroid gland itself, but without increasing 
the TSH blood level. With this condition fulfilled, there is a lower 
risk of early, transient exacerbation of hyperthyroidism caused by 
an increased release of thyroid gland hormones from radioactively 
damaged thyreocytes into the blood stream [2]. 
When qualifying patients for treatment, it is indispensable that 
the scintigraphy of the thyroid gland is performed, as well as iodine 
uptake tests, the results of which can be used for calculating the 
effective half-life for Marinelli’s formula [20]. This kind of diagnos-
tic allows precise imaging of the gland, as well as a quantitative 
assessment of its functioning. It also enables the physician to 
calculate the extent to which iodine uptake is prevented in the 
tissue adjacent to the nodules. The information is essential for 
establishing the target thyroid absorbed radiation dose, i.e. 
the basic component of the modified Marinelli formula used for 
calculating the correct therapeutic activity of capsule. It was as-
sumed that, given a rising proportion of radioiodine uptake in 
nodules in relation to the uptake in the entire gland (or, in other 
words, increasing suppression of surrounding tissue), the thyroid 
absorbed radiation dose should be proportionately higher. The 
above premise is based on the knowledge of the physical pro-
perties of radiation and the fundamental principles concerning 
the interaction of radiation with matter. Assuming that the medium 
range of b radiation emitted by 131I in tissue is as low as 0.4 mm, 
then with fully suppressed normal tissue (I degree of suppression 
in our study) the entire radiation dose is bound to be taken up 
by the nodule. Therefore, only the nodule is destroyed, possibly 
with only a small margin of surrounding tissue [1]. The maximum 
absorbed dose adopted in our Department is 400 Gy for both au-
tonomous and multinodular goitre, which is a commonly accepted 
value [8, 21, 22]. In those patients whose normal tissue adjacent 
to nodules is not fully suppressed (II and III degree in the Depart-
ment), we used appropriately lower absorbed doses. The above 
findings seem to be corroborated by the fact that the greatest 
proportion of euthyroidism was observed in patients with the 1st 
degree suppression of normal tissue, both in the case of solitary 
and multinodular goitres. Therefore, Okosieme et al.’s claim that 
scintigraphy of the thyroid gland which images the distribution of 
radioiodine in the thyroid tissue does not have any bearing on the 
outcome of treatment seems to stem from inadequate understand-
ing of the significance of radioisotopic diagnostic investigation for 
radioiodine therapy of thyroid disorders [3].
The evaluation of the effective half-life and iodine uptake in the 
thyroid is also crucial because the therapeutic activity of a given 
absorbed dose is inversely proportional to the values of these 
parameters (as both of them are in the denominator of the modi-
fied Marinelli formula). In other words, when the values of iodine 
uptake and effective half-life drop, the therapeutic activity of 131I 
grows. To avoid exceeding national limits for therapeutic activity 
(800 MBq), we assumed that the lower threshold for iodine uptake 
in radioiodine therapy patients is 20%, since below this value 
therapeutic activities calculated by the Marinelli formula — even for 
medium-sized glands — were frequently higher than 800 MBq [23]. 
The effective half-life of radioiodine depends on its biological 
half-life. It is usually the case that the less acute hyperthyroidism 
was before treatment, the longer the biological half-life of radio-
iodine. Thus the values of thyroxine and triiodothyronine in pa-
tients who are qualified for treatment in our Department are usually 
only slightly above the norm. In both analysed subgroups, Teff. va-
Figure 8. Changes in mean concentrations of fT4 in studied patients 
within 12 months after 131I administration
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lues were not lower than 5 days. Having analysed the above data, 
and having considered the work of such researchers as Gupta and 
Abos, who use fixed therapeutic doses and do not perform iodine 
uptake tests in their patients, it can be concluded that one of the 
reasons for lower treatment efficacy (78% of euthyroidism, 90% 
in our institution) in patients treated in this way is the fact that the 
target absorbed doses are not correlated with the iodine uptake 
capacity, iodine effective half-life in the thyroid or the volume of 
the gland [17]. Therefore, in the case of post-therapy hypothyroid-
ism, the thyroid absorbed dose was probably too high, while in 
hyperthyroid patients it might have been too low. 
Moreover, when analysing the results we noticed that, contrary 
to expectations, moderate enlargement of the thyroid gland (i.e. by 
30–60 ml) does not adversely affect the efficacy of radiotherapy, but 
even enhances it (Table 4). This can be explained by the fact that, 
given mild thyroid enlargement after radiotherapy, the amount of 
glandular tissue damaged by the first dose of 131I is proportionately 
greater, which, to a certain extent, prevents hypothyroidism and 
increases the efficacy of toxic goiter treatment. 
Conclusions 
Hyperthyroid patients with nodular goitres qualified for radioio-
dine therapy should have the lowest possible TSH blood levels in 
order to minimise the risk of post-radiation damage to the gland 
tissue surrounding the nodule. 
Serum concentrations of fT3 and fT4 before treatment should 
be around the upper limit of normal so as to minimise possible 
exacerbation of transitory hyperthyroidism resulting from a sudden 
release of hormones from the damaged thyreocytes. 
In each case, scintigraphy and iodine uptake tests should 
be carried out, and the percentage of radioiodine uptake in no-
dules established, relative to the uptake in the entire gland. Only 
the knowledge of this ratio makes it possible to determine the 
appropriate absorbed radiation dose. 
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